Please select the option that best describes you:
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
Would you consider re-challenging this patient with a TKI in the future? If so, which TKI would you use?